Navigation Links
KV Pharmaceutical Enters Into Consent Decree With FDA
Date:3/2/2009

Decree outlines path forward to resume manufacturing at KV facilities

ST. LOUIS, March 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) today announced that it has entered into a consent decree with the U.S. Food and Drug Administration (FDA) regarding the company's drug manufacturing and distribution. The decree provides a series of measures that, when satisfied, will permit KV to resume the manufacture and distribution of products marketed by its subsidiaries, ETHEX and Ther-Rx. The Company is working expeditiously to satisfy the requirements and expects to provide further information in upcoming communications.

As part of the consent decree, KV has agreed not to market products it manufactures until it has satisfied certain requirements designed to demonstrate compliance with FDA's current good manufacturing practices (CGMP) regulations. KV has also agreed that it will not distribute certain products, including its prenatal vitamins and hematinic products, until the products are approved by FDA's ANDA or NDA processes.

"We have been working diligently with the FDA for the last two months to reach agreement on a clear path forward to permit KV to resume manufacturing and marketing its products," said David A. Van Vliet, KV's Interim Chief Executive Officer. "Since December, when new management took over at KV, our team has taken significant steps to enhance our systems and procedures, and we will continue to do so. We look forward to cooperating with the FDA during this process that will facilitate our return to the market. Predicting the timing for the return and the ultimate product assortment that we will market are presently very difficult due to the range of variables that must be managed. As we gain certainty, we will notify customers and all other stakeholders."

The consent decree provides that, before resuming manufacturing, KV will have an independent thir
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Epistem Announces Research and Development Collaboration With a Major Pharmaceutical Company
3. Simcere Pharmaceutical Group to Announce 2008 Fourth Quarter and Full Year Earnings On Thursday, March 12, 2009
4. Immtech and Beijing Pharmaceutical Group Co. Sign Memorandum of Understanding to Explore Developing Strategic Business Alliance
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
7. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
8. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
9. Eiger BioPharmaceuticals Raises $7.1 Million A Round
10. Angiotech Pharmaceuticals announces time change of conference call and webcast
11. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 VG Life Sciences, Inc., ... autoimmune and infectious diseases, announced that the U.S. ... important new composition of matter patent covering methods ... of CLIP. U.S. Patent No. ... Life Sciences, VG1177, a synthetic peptide which has ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... Yongye Biotechnology,International, Inc. (OTC Bulletin Board: YGYB; "Yongye" ... of nutrients for plants and,animals, located in the ... management will present at the upcoming Roth 21st ... , The date, time, ...
... today announced the appointment of Babatunde A. Otulana, M.D., ... medical officer.Dr. Otulana, 52, will provide medical as well ... it moves forward with the development of AerovantTM for ... has more than 20 years of experience in pulmonary ...
... Stock Exchange Symbol: LRILAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ - ... "Company"), a Canadian based global non-clinical contract research organization ... Officer of the Company, will be presenting at the ... 11, 2009 at 9.30 am at the Waldorf Astoria ...
Cached Biology Technology:Yongye Biotechnology to Present at Roth Conference 2Yongye Biotechnology to Present at Roth Conference 3Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer 2
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... of the Institute of Tropical Medicine (ITG) discovered a parasite ... but at the same time had become better in withstanding ... in developing a superbug. For it appears the battle against ... "To our knowledge it is the first time such a ...
... The Danish National Advanced Technology Foundation is donating ... brings together Denmark,s leading players within the sustainable use ... Mller Mrsk, Novozymes, Haldor Topse, Man Diesel & Turbo ... for the parties, joint research aimed at developing specific ...
... in recent years that wild chilies develop their trademark pungency, or ... seeds. But that doesn,t explain why some chilies are hot and ... growing in dry areas need more water to produce as many ... a threat in dryer environments so chilies in those areas are ...
Cached Biology News:Do our medicines boost pathogens? 2Do our medicines boost pathogens? 3New research platform paves way for future bio-based society 2To turn up the heat in chilies, just add water 2
See product name for description....
... Custom Production Service - Conjugation ... Conjugation Biotin Conjugation Fluorescein Isothiocyanate ... Conjugation Allophycocyanin Conjugation Alexa Fluor ... Alexa Fluor 405 Conjugation Rpe-Alexa ...
... Design , Customer Peptide Synthesis , 20 Amino Acid ... , 20 mg will return to customer for future usage ... 2 , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ...
Request Info...
Biology Products: